People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Melt Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $53.7M | $510.9M | 2023 |
| Mid-America Imaging, LLC | — | Other Health Care | Pre-Seed | $100K | $157K | — |
Brad Osborne at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brad Osborne on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Lisa Arington | 1 | 8 |
| Rick Lonigro | 1 | 6 |
| Scott Sankey | 1 | 6 |
| Mark Baum | 1 | 4 |
| Gregory Glesinger | 1 | 4 |
| Larry Dillaha | 1 | 3 |
| Andrew Boll | 1 | 3 |
| John Berdahl | 1 | 3 |
| Randall Duncan | 1 | 2 |
| Karl Gack | 1 | 2 |
| Gregory Madison | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.